DBV Technologies SA - American (DBVT)
NASDAQ:DBVT
Top Page
DBV Technologies SA - American
(NASDAQ:DBVT)
Select Model
Select Model
Rating:52Neutral
Price Target:
$20.00
▼(-2.20% Downside)
Action:ReiteratedDate:03/28/26
The score is held back primarily by weak financial performance (ongoing losses, zero recent revenue, and sustained cash burn). Technicals are mixed with negative near-term momentum, and valuation metrics provide little support due to non-meaningful P/E and no dividend. Offsetting these risks, the recent positive Phase 3 peanut patch data is a meaningful catalyst that improves the outlook but does not eliminate financing and execution risk.
Positive Factors
Phase 3 efficacy (Viaskin Peanut)
Robust Phase 3 efficacy materially raises the probability of regulatory approval and supports a credible commercialization thesis. As the largest pediatric peanut immunotherapy trial with consistent sensitivity analyses, these durable results strengthen long-term market positioning and partner interest if approval is achieved.
Negative Factors
Sustained cash burn
Persistent negative operating and free cash flow creates a durable funding dependency on external capital or partnerships. Over the medium term this raises dilution risk, can constrain R&D pacing, and may force suboptimal deal terms or program delays if capital markets tighten or milestones slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 efficacy (Viaskin Peanut)
Robust Phase 3 efficacy materially raises the probability of regulatory approval and supports a credible commercialization thesis. As the largest pediatric peanut immunotherapy trial with consistent sensitivity analyses, these durable results strengthen long-term market positioning and partner interest if approval is achieved.
Read all positive factors
DBV Technologies SA - American (DBVT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.15B
Dividend YieldN/A
Average Volume (3M)267.23K
Price to Earnings (P/E)―
Beta (1Y)-0.01
Revenue GrowthN/A
EPS Growth1.29%
CountryUS
Employees106
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.24
Shares Outstanding55,670,418
10 Day Avg. Volume264,167
30 Day Avg. Volume267,229
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)3.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.42
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-30.89
Enterprise Value/Ebitda-4.06
Forecast
1Y Price Target
$46.40Price Target Upside126.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.86
Revenue Forecast (FY)$4.81M
DBV Technologies SA - American Business Overview & Revenue Model
Company Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase II...
How the Company Makes Money
DBV Technologies has historically generated little to no recurring revenue from commercial product sales because it has been a clinical-stage biotechnology company without widely marketed, approved products. Its cash inflows have therefore primari...
DBV Technologies SA - American Earnings Call Summary
Earnings Call Date:Jul 30, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:May 04, 2026
Earnings Call Sentiment Positive
The earnings call presents a positive outlook with significant progress in Viaskin Peanut development and financial management. However, regulatory challenges and increased operating expenses pose some concerns. The overall sentiment is cautiously optimistic with a positive tilt due to successful trial milestones and extended cash runway.Positive Updates
Viaskin Peanut Development Progress
Successful results from the Phase III efficacy study, EPITOPE, for toddlers aged 1 to 3 years met its primary endpoint. Enrollment for the VITESSE Phase III trial in children aged 4 to 7 years is expected to complete by the end of Q3 2024.
Negative Updates
Regulatory Challenges with FDA
Ongoing discussions with the FDA regarding the COMFORT Toddlers supplemental safety study, particularly concerning patch wear-time experience, indicating a delay in protocol alignment.
Read all updates
Q2-2024 Updates
Positive
Negative
Viaskin Peanut Development Progress
Successful results from the Phase III efficacy study, EPITOPE, for toddlers aged 1 to 3 years met its primary endpoint. Enrollment for the VITESSE Phase III trial in children aged 4 to 7 years is expected to complete by the end of Q3 2024.
Read all positive updates
Company Guidance
During the DBV Technologies Q2 2024 earnings call, the company provided several key updates on its development programs and financial outlook. DBV is advancing its Viaskin Peanut candidate for treating peanut allergies in children aged 1 to 7. The VITESSE Phase III trial for children aged 4 to 7 is progressing well, with patient enrollment expected to complete by the end of Q3 2024. The company is also addressing the FDA's feedback on its COMFORT Toddlers supplemental safety study, which supports the Biologics License Application for the 1 to 3 age group. Additionally, DBV Technologies has extended its cash runway into Q1 2025 due to cost-saving measures, despite a net loss of $60.5 million in H1 2024. The company remains focused on achieving regulatory approval and advancing its clinical trials, with anticipated milestones set for the remainder of the year.DBV Technologies SA - American Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 15.73M | 4.80M | 5.71M |
| Gross Profit | -17.67M | -6.81M | 15.73M | -15.50M | -3.56M |
| EBITDA | -135.49M | -110.99M | -63.27M | -76.68M | -91.16M |
| Net Income | -147.40M | -113.72M | -72.73M | -96.30M | -97.81M |
Balance Sheet | |||||
| Total Assets | 233.72M | 65.66M | 182.99M | 246.52M | 146.32M |
| Cash, Cash Equivalents and Short-Term Investments | 194.17M | 32.46M | 141.37M | 209.19M | 77.30M |
| Total Debt | 21.68M | 7.80M | 6.55M | 4.15M | 10.66M |
| Total Liabilities | 64.95M | 38.27M | 42.80M | 52.06M | 47.29M |
| Stockholders Equity | 168.77M | 27.39M | 140.19M | 194.45M | 99.03M |
Cash Flow | |||||
| Free Cash Flow | -121.18M | -106.81M | -80.33M | -56.45M | -109.16M |
| Operating Cash Flow | -121.18M | -104.47M | -79.65M | -55.70M | -108.24M |
| Investing Cash Flow | -1.37M | -757.00K | -808.00K | -100.00K | -433.00K |
| Financing Cash Flow | 276.18M | 587.00K | 6.77M | 194.10M | 274.00K |
DBV Technologies SA - American Technical Analysis
Positive
20.45
Price Trends
21.40
Negative
19.28
Positive
15.21
Positive
Market Momentum
-0.20
Negative
49.00
Neutral
56.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DBVT, the sentiment is Positive. The current price of 20.45 is above the 20-day moving average (MA) of 20.30, below the 50-day MA of 21.40, and above the 200-day MA of 15.21, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 49.00 is Neutral, neither overbought nor oversold. The STOCH value of 56.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DBVT.
DBV Technologies SA - American Risk Analysis
DBV Technologies SA - American disclosed 76 risk factors in its most recent earnings report. DBV Technologies SA - American reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
DBV Technologies SA - American Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $370.80M | -2.27 | 12.82% | ― | 1268.81% | ― | |
52 Neutral | $1.15B | -3.63 | -189.50% | ― | ― | 1.29% | |
52 Neutral | $523.57M | -1.68 | -137.70% | ― | ― | -67.41% | |
52 Neutral | $522.77M | -3.10 | -47.27% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $200.62M | -0.64 | -115.95% | ― | ― | 21.61% | |
49 Neutral | $467.49M | -53.29 | -67.33% | ― | ― | 4.97% |
* Healthcare Sector Average
DBVT
DBV Technologies SA - American
20.45
13.38
189.25%
LRMR
Larimar Therapeutics
5.04
3.16
168.09%
KRRO
Korro Bio
13.91
0.35
2.58%
FDMT
4D Molecular Therapeutics
10.24
7.48
271.01%
PRTC
PureTech Health
15.55
0.38
2.47%
LXEO
Lexeo Therapeutics, Inc.
6.31
3.95
167.37%
DBV Technologies SA - American Corporate Events
Business Operations and StrategyProduct-Related Announcements
DBV Technologies Highlights Positive Phase 3 Peanut Patch Data
Positive
Mar 2, 2026
On February 28, 2026, DBV Technologies reported additional positive Phase 3 data for its VIASKIN Peanut Patch from the VITESSE trial, presented at the AAAAI 2026 Annual Meeting in Philadelphia. The study, the largest food allergy immunotherapy tri...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.